Efficacy and acceptability of intravenously administered sulprostone, a tissue-selective prostaglandin-E2 derivative, for induction of first-trimester abortion.
The abortifacient effect of a new tissue-selective prostaglandin E2-derivative, sulprostone, administered intravenously, has been investigated in 166 women in the the first trimester of pregnancy. Four different dose schedules (1.7 mcg/min for 5 or 10 hour--total dose 500 mcg or 1000 mcg, 2.8 mcg/min and 4.1 mcg/min for 6 hours--total dose 1000 mcg and 1500 mcg) have been evaluated. No absolute failures occurred and no severe complications or side-effects were recorded. Best results (high abortifacient efficacy and low systemic side-effects) were obtained by infusing 1000 mcg sulprostone in appr. 10 h. Our study indicates that sulprostone appears to have a high degree of acceptability.
D000019:Abortifacient Agents / Q000008:administration & dosage / Q000009:adverse effects; D000028:Abortion, Induced; D000293:Adolescent; D000328:Adult; D015232:Dinoprostone / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects
D000019:Abortifacient Agents; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone